Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 301

1.

Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.

Kobelt G, Jönsson L, Gerdtham U, Krieglstein GK.

Graefes Arch Clin Exp Ophthalmol. 1998 Nov;236(11):811-21.

PMID:
9825256
3.
5.
7.

The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.

Holmstrom S, Buchholz P, Walt J, Wickstrøm J, Aagren M.

Curr Med Res Opin. 2006 May;22(5):897-905.

PMID:
16709311
8.

Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Easthope SE, Perry CM.

Drugs Aging. 2002;19(3):231-48. Review.

PMID:
12027782
9.

A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective.

Hommer A, Wickstrøm J, Friis MM, Steeds C, Thygesen J, Ferreras A, Gouws P, Buchholz P.

Curr Med Res Opin. 2008 Apr;24(4):1057-63. doi: 10.1185/030079908X280626 . Epub 2008 Feb 29.

PMID:
18315942
10.

Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.

Liu JH, Medeiros FA, Slight JR, Weinreb RN.

Ophthalmology. 2009 Mar;116(3):449-54. doi: 10.1016/j.ophtha.2008.09.054. Epub 2009 Jan 20.

PMID:
19157559
12.

Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices.

Pajic B; Conductors of the Swiss COSOPT Survey (CSCS).

Curr Med Res Opin. 2003;19(2):95-101.

PMID:
12740152
15.

[An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients].

Rouland JF, Peigne G, Sellem E, Renard JP, Williamson W, Filippi JM, Cohn H, Hamard P, Abellan P, Chagnon A, Malet F, Haye I.

J Fr Ophtalmol. 2001 Mar;24(3):233-43. French.

17.

Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.

Lesk MR, Koulis T, Sampalis F, Sampalis JS, Bastien NR.

Ann Pharmacother. 2008 Apr;42(4):498-504. doi: 10.1345/aph.1K565. Epub 2008 Mar 25.

PMID:
18364402
18.
19.

Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.

Rouland JF, Le Pen C, Benhaddi H, Piriou E, Lilliu H, Kenigsberg PA; Glaucoma Study Group.

Eur J Ophthalmol. 2005 Sep-Oct;15(5):562-80.

PMID:
16167287
20.

Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.

Payet S, Denis P, Berdeaux G, Launois R.

Clin Drug Investig. 2008;28(3):183-98.

PMID:
18266403
Items per page

Supplemental Content

Write to the Help Desk